Trial Profile
A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Vilanterol/fluticasone furoate (Primary) ; Salbutamol; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms CAPTAIN
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 09 Nov 2022 Results assessing the relationship between Asthma Control Questionnaire (ACQ) scores and exacerbation rates, healthcare resource utilization (HCRU), and utility values in adults with moderate-to-severe asthma presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 19 Oct 2022 Results assessing to explore potential differential treatment responses by examining asthma control (measured by the Asthma Control Questionnaire-6 [ACQ-6]) by age as a continuous variable in the CAPTAIN study, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
- 08 Nov 2021 Post-hoc analysis results d the impact of adding Umeclidinium and/or increasing Fluticasone Furoate dose in subgroups defined by baseline IgE levels, presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.